Table 2. Summary of Treatment-Emergent Adverse Events (TEAEs).
| Patients | No. (%) | ||
|---|---|---|---|
| Deutetrabenazine | Placebo (n = 51) | ||
| High dose (n = 52) | Low dose (n = 54) | ||
| Any TEAE | 34 (65) | 24 (44) | 25 (49) |
| Treatment-related TEAE | 25 (48) | 14 (26) | 7 (14) |
| Serious TEAE | 1 (2) | 0 | 0 |
| Serious treatment-related TEAE | 0 | 0 | 0 |
| TEAE leading to | |||
| Death | 0 | 0 | 0 |
| Study drug discontinuation | 3 (6) | 0 | 1 (2) |
| Dose interruption | 2 (4) | 1 (2) | 1 (2) |
| Dose reduction | 3 (6) | 0 | 0 |
| Most common (>4%) TEAEs in any treatment group | |||
| Somnolence | 8 (15) | 2 (4) | 1 (2) |
| Headache | 6 (12) | 8 (15) | 4 (8) |
| Nasopharyngitis | 6 (12) | 2 (4) | 3 (6) |
| Fatigue | 5 (10) | 1 (2) | 0 |
| Increased appetite | 4 (8) | 1 (2) | 0 |
| Vomiting | 3 (6) | 1 (2) | 4 (8) |
| Tic | 3 (6) | 0 | 1 (2) |
| Nausea | 2 (4) | 3 (6) | 0 |
| Pain in extremity | 2 (4) | 0 | 3 (6) |